Welcome to our dedicated page for Upstream Bio SEC filings (Ticker: UPB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Upstream Bio, Inc. (NASDAQ: UPB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances verekitug, a monoclonal antibody targeting the thymic stromal lymphopoietin (TSLP) receptor, through clinical development. As a clinical-stage biotechnology company, Upstream Bio uses SEC reports to communicate trial progress, financial results, and other material information relevant to shareholders.
Recent Form 8-K filings referenced by the company include announcements of quarterly financial results and business highlights, as well as the furnishing of press releases and presentations. For example, an 8-K dated August 6, 2025, furnished a press release summarizing second quarter financial results and updates on Phase 2 trials in CRSwNP, severe asthma, and COPD. Another 8-K dated November 5, 2025, furnished third quarter results and program progress, while an 8-K dated September 2, 2025, furnished the press release and presentation describing positive top-line data from the VIBRANT Phase 2 CRSwNP trial.
Through these filings, investors can see how Upstream Bio reports collaboration revenue, research and development expenses related to verekitug, general and administrative expenses, and net loss figures, as well as balance sheet items such as cash, cash equivalents, and short-term investments. The filings also describe the design and endpoints of key clinical trials when they are the subject of a furnished press release.
On Stock Titan, these documents are supplemented with AI-powered summaries that highlight the main points of each filing, helping readers quickly understand what changed in a given quarter or event filing. Users can review 8-Ks tied to clinical data releases, financial updates, and other corporate communications, and use this information alongside news and price data when evaluating UPB.
Upstream Bio, Inc. director Erez Chimovits reported receiving a stock option grant covering 17,096 shares of common stock. The options have an exercise price of $6.69 per share and expire on June 8, 2036. They vest in full on the earlier of June 9, 2027 or the next Annual Meeting of Stockholders, subject to his continued service. Under an agreement with OrbiMed-affiliated entities, any securities or economic benefits from this award are to be transferred to those OrbiMed funds.
Upstream Bio, Inc. reported the results of its 2026 annual stockholder meeting. Stockholders elected Class II directors H. Edward Fleming, Jr., M.D. and Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A. to serve until the 2029 annual meeting, with each nominee receiving strong majority support.
Stockholders also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. The meeting had a quorum, with most outstanding shares represented in person or by proxy, and no other matters were submitted for a vote.
Upstream Bio, Inc. reports a Schedule 13G/A amendment disclosing shared beneficial ownership by Decheng entities. The amendment states that 2,724,868 shares of Common Stock were beneficially owned by Decheng Capital Global Life Sciences Fund IV, L.P. as of March 31, 2026, representing 5.0% of the class based on 54,419,986 shares outstanding as of March 20, 2026. The filing explains that voting and dispositive authority over those shares is shared by GP entities and that Dr. Xiangmin Cui holds managerial authority.
Upstream Bio, Inc. reported a wider quarterly loss as it advances its lead drug candidate verekitug through multiple mid‑stage trials. For the three months ended March 31, 2026, collaboration revenue from its Maruho agreement was $1.0 million, while research and development expenses rose to $36.6 million and general and administrative costs were $8.1 million.
This drove a net loss of $40.6 million, compared with $27.3 million a year earlier, and a net loss per share of $0.75. The company ended the quarter with $294.6 million in cash, cash equivalents and short‑term investments and expects this to fund operations through 2027 as it runs Phase 2 studies in severe asthma, CRSwNP and COPD and prepares Phase 3 programs for asthma and CRSwNP.
Upstream Bio, Inc. reported first quarter 2026 results and highlighted progress across its verekitug clinical programs in severe asthma, CRSwNP and COPD. The company held cash, cash equivalents and short-term investments of $294.6 million as of March 31, 2026, which it expects will fund planned operations through 2027.
Collaboration revenue was $1.0 million for the quarter. Research and development expenses rose to $36.6 million, and general and administrative expenses were $8.1 million, reflecting higher clinical, manufacturing and personnel costs. Net loss widened to $40.6 million compared with $27.3 million a year earlier.
The company is preparing for End-of-Phase 2 FDA meetings in mid-2026 and plans to initiate Phase 3 trials of verekitug in severe asthma and CRSwNP in the first quarter of 2027. It is also capping enrollment in its Phase 2 VENTURE COPD study, with efficacy data expected in the second half of 2027.
Upstream Bio, Inc. is calling a virtual 2026 annual stockholder meeting on June 9, 2026 at 9:00 a.m. Eastern Time. Holders of its 54,419,986 outstanding common shares as of April 13, 2026 may vote online on two main items: electing two Class II directors, H. Edward Fleming, Jr., M.D. and Liam Ratcliffe, M.B.Ch.B., Ph.D., M.B.A., to new three‑year terms, and ratifying PricewaterhouseCoopers LLP as independent auditor for the 2026 fiscal year. The company uses “notice and access” to distribute proxy materials electronically, remains an emerging growth and smaller reporting company, and describes its board structure, committee responsibilities, director pay, and executive compensation, including stock‑based incentives and a formal executive severance plan tied to change‑in‑control events.
Upstream Bio, Inc. entered into a Sales Agreement with Leerink Partners LLC to establish an at-the-market equity program. Under a related prospectus supplement, the company may offer and sell shares of its common stock in an aggregate amount of up to $150,000,000 through or to the agent.
Leerink Partners will use commercially reasonable efforts to place shares on Nasdaq or other trading markets and will receive a commission of up to 3.0% of gross proceeds from each sale. Neither party is obligated to sell a minimum amount, and the company or the agent may suspend or terminate the program at any time, subject to the agreement’s terms.
The shares will be issued under Upstream Bio’s automatic shelf registration statement on Form S-3ASR and the prospectus supplement filed on March 26, 2026. Legal opinions from Goodwin Procter LLP regarding the validity of the shares are included as exhibits.
Upstream Bio, Inc. has entered into a sales agreement with Leerink Partners LLC to offer and sell, from time to time, shares of its common stock in an at-the-market offering of up to $150,000,000. The sales agent may sell shares on Nasdaq consistent with market conditions and will receive compensation up to 3.0% of gross proceeds. An illustrative offering at the March 24, 2026 last reported sale price of $8.45 per share would equal $150.0 million or approximately 17,751,479 shares; shares outstanding were 54,237,750 as of December 31, 2025. The prospectus supplement highlights that proceeds treatment, timing and quantities will vary with market conditions, and that the sales agent will be deemed an underwriter for purposes of the Securities Act.
Upstream Bio, Inc. is a clinical-stage biotechnology company focused on inflammatory diseases, initially severe respiratory disorders. Its lead and only product candidate, verekitug, is a fully human monoclonal antibody that blocks the receptor for thymic stromal lymphopoietin (TSLP), a key upstream driver of inflammation.
Verekitug has shown high TSLP receptor occupancy, a favorable safety profile and strong, sustained reductions in asthma biomarkers (eosinophils and FeNO) for up to 24 weeks after dosing in early trials, supporting extended dosing intervals. The company has completed Phase 2 studies in severe asthma and chronic rhinosinusitis with nasal polyps with positive top-line results, and has initiated a Phase 2 trial in COPD and a long-term asthma extension study.
Upstream Bio plans to start Phase 3 trials in severe asthma and CRSwNP in the first quarter of 2027, aiming for high efficacy without biomarker restrictions and quarterly at-home administration. Management sees broader potential for verekitug across multiple TSLP-driven diseases beyond its initial respiratory indications.